These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1746534)

  • 21. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.
    Preisler HD; Rustum Y; Henderson ES; Bjornsson S; Creaven PJ; Higby DJ; Freeman A; Gailani S; Naeher C
    Blood; 1979 Mar; 53(3):455-64. PubMed ID: 760861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The continuous-DCMP therapy for acute nonlymphocytic leukemia in elderly patients--comparison with younger patients].
    Ito T; Yamamoto K; Kinoshita T; Sugiura I; Saito M; Ono Y; Hayashi K; Nagata K; Kamiya O; Ohara K
    Rinsho Ketsueki; 1989 Apr; 30(4):421-8. PubMed ID: 2769965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
    Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E
    Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
    Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
    Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cytosine arabinoside in the treatment of childhood malignancies.
    Lie SO; Slørdahl S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):160-5. PubMed ID: 3859931
    [No Abstract]   [Full Text] [Related]  

  • 31. Remission induction in acute nonlymphocytic leukemia: comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin.
    Preisler H; Bjornsson S; Henderson ES; Hryniuk W; Higby D; Freeman A; Naeher C
    Med Pediatr Oncol; 1979; 7(3):269-75. PubMed ID: 542191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical use of cytosine arabinoside in childhood. II. Cytosine arabinoside in the prevention and therapy of leukemic meningosis].
    Masi M; Paolucci P; Vivarelli F; Vecchi V
    Minerva Pediatr; 1975 Sep; 27(30):1624-31. PubMed ID: 1058332
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
    Keskin A; Tombuloğlu M; Atamer MA; Büyükkeçeci F
    Acta Haematol; 1994; 92(1):14-7. PubMed ID: 7985476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
    Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
    Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of acute leukemias].
    Gross R; Gerecke D
    Wien Klin Wochenschr; 1982 Nov; 94(21):591-6. PubMed ID: 6963072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
    Takahashi I; Hara M; Uchida K; Takaoka K; Watanabe S; Lai M; Hamasaki K; Kohi F; Kitajima K; Kimura I; Adachi T; Yorimitsu S; Tokioka M; Sanada H
    Acta Med Okayama; 1982 Feb; 36(1):77-80. PubMed ID: 6950658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intensive post-remission therapy of acute myeloid leukemia with high doses of cytosine arabinoside].
    Slechtová J; Koza V; Svojgrová M; Cepelák V
    Cas Lek Cesk; 1989 Sep; 128(39):1239-42. PubMed ID: 2582468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.